Challenges and controversies in resectable non-small cell lung cancer: a clinician's perspective

Ilias Houda, Chris Dickhoff, Carin A. Uyl-de Groot, Ronald A.M. Damhuis, Noemi Reguart, Mariano Provencio, Antonin Levy, Rafal Dziadziuszko, Cecilia Pompili, Massimo Di Maio, Michael Thomas, Alessandro Brunelli, Sanjay Popat, Suresh Senan, Idris Bahce

Research output: Contribution to journalReview articleAcademicpeer-review

4 Citations (Scopus)


The treatment landscape of resectable early-stage non-small cell lung cancer (NSCLC) is transforming due to the approval of novel adjuvant and neoadjuvant systemic treatments. The European Medicines Agency (EMA) recently approved adjuvant osimertinib, adjuvant atezolizumab, adjuvant pembrolizumab, and neoadjuvant nivolumab combined with chemotherapy, and the approval of other agents or new indications may follow soon. Despite encouraging results, many unaddressed questions remain. Moreover, the transformed treatment paradigm in resectable NSCLC can pose major challenges to healthcare systems and magnify existing disparities in care as differences in reimbursement may vary across different European countries. This Viewpoint discusses the challenges and controversies in resectable early-stage NSCLC and how existing inequalities in access to these treatments could be addressed.

Original languageEnglish
Article number100841
JournalThe Lancet Regional Health - Europe
Publication statusPublished - Mar 2024


  • Access to primary care
  • Adjuvant chemotherapy
  • Biomarkers
  • Disease-free survival
  • Europe
  • Humans
  • Immune checkpoint inhibitors
  • Lung neoplasms
  • Non-small-cell lung cancer
  • Protein kinase inhibitors
  • Surgery
  • United States
  • United States Food and Drug Administration

Cite this